ABBVAbbVieNot started yet
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
Extensive Stage-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 80 (planned)
- Started
- Nov 4, 2026
- Main results expected
- Aug 2031
- Fully finished
- Aug 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response (OR) measured by overall response rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measured over: Up to Approximately 4 Years
Number of Participants with Adverse Events (AEs)
Measured over: Up to Approximately 4 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07895056 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC